1:06 PM
 | 
Jul 19, 2018
 |  BC Extra  |  Company News

Kite, Gadeta in gamma delta T cell deal

Kite Pharma Inc. and Gadeta B.V. (Utrecht, the Netherlands) partnered to develop T cell therapies that express gamma delta TCRs for hematologic malignancies and solid tumors using Gadeta's platform. Kite, a subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), will obtain an undisclosed upfront equity purchase in Gadeta and will have an exclusive option to acquire the company.

According to BioCentury's BCIQ database, the deal is the first disclosed for Gilead in the gamma delta space. Gilead is at least the second large biopharma to acquire a stake in a smaller...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >